Thrombolex is committed to helping provide a new standard of care for the treatment of arterial and venous thromboembolic (A+VTE) conditions. Discover our innovative approach to treatment with the BASHIR™ Family of Endovascular Catheters.
An Elegant, Novel Solution
For Optimal Thrombus Resolution
The Problem
Treating A+VTE safely and effectively while minimizing risk, maximizing clot burden resolution, and producing consistent clinical outcomes is of critical importance.
Our Solution
The unique hybrid mechanism of action of the BASHIR™ family of endovascular catheters allows the use of both mechanical and pharmacological treatment to immediately restore blood flow. This allows for the efficient and safe introduction of thrombolytics to produce positive clinical outcomes.
Product Resources
Product Overview • Product Details
Clinical Resources
Clinical Studies • Instructional Videos
Our Company
Our Mission • Our Leadership
Our Family of Catheters
For restoring blood flow in peripheral and pulmonary vessels
The catheter’s expandable infusion basket allows a controlled and selective infusion of physician-specified fluids.
Available in 7F and 8F sizes.
For restoring blood flow within shorter peripheral and pulmonary vessels
The short basket of the S-B catheter allows navigation and implementation in shorter, more tortuous vessels.
Available in 7F and 8F sizes.
For restoring blood flow in peripheral vessels with extensive thrombus burden
A family of catheters designed to deliver thrombolytics through the expandable infusion basket and along a segment of the catheter shaft.
–
Featured News
Thrombolex Announces Enrollment of 100th Patient in RAPID-PE Clinical Study
New Britain, PA, May 4, 2026 — Thrombolex, Inc., a medical device company dedicated to advancing minimally invasive endovascular treatment of venous thromboembolism (VTE), today announced the enrollment of the 100th patient in the RAPID-PE clinical study. This...
Thrombolex Secures $50M Series A Financing to Advance Endovascular Treatment for Pulmonary Embolism and Venous Thrombus
New Britain, PA, March 16, 2026 – Thrombolex, Inc., a commercial-stage medical device company advancing a differentiated pharmaco-mechanical lysis (PML) platform for the treatment of pulmonary embolism (PE) and other thromboembolic diseases, announced the closing of a...
Interim Data from the RAPID-PE Study Presented at TCT 2025
New Britain, PA - (October 28th, 2025) - Thrombolex, Inc. presented the prespecified interim analysis from the first 50 patients in RAPID-PE, a prospective, multicenter U.S. study evaluating On-The-Table (OTT) pharmaco-mechanical lysis (PML) without any post procedure...
RESCUE-II Study results published in JACC: Advances
New Britain, PA – (June 25, 2025) – Thrombolex, Inc., a medical device manufacturer committed to advancing solutions for the treatment of arterial and venous thromboembolic diseases, announced the publication of the results from the RESCUE-II Study in JACC: Advances....
Rescue II Results
RESCUE II Trial Demonstrates the Feasibility of On-The-Table Pharmacomechanical Lysis without Post-Procedure Infusion in Treating Acute Pulmonary Embolism NEW BRITAIN, PA (October 28, 2024) — Christian Bichard, MD presented the results of the RESCUE-II Trial during...
RAPID-PE Study News
Thrombolex Announces the First Two Patients enrolled in the RAPID-PE Clinical Study evaluating an Advanced On-The-Table Protocol for the Treatment of Pulmonary Embolism NEW BRITAIN, PA (October 23, 2024) — Thrombolex, Inc. announced the enrollment of the first two...
Do more with less.
It is the standard we hold ourselves to - in the design of the BASHIR® Family of Endovascular Devices, in the clinical programs we invest in, and in the resources we make available to the interventional community.
From single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) to a portfolio built to address the full spectrum of A&VTE, every element of what Thrombolex offers is grounded in one conviction: that better outcomes, efficient delivery, and clinical confidence should be accessible to every clinician and every patient who needs them.
Thrombolex.com #Thrombolex ... See MoreSee Less
0 CommentsComment on Facebook
Pulmonary embolism and venous thrombus require targeted, reliable intervention, and the BASHIR® Family of Endovascular Devices is built to deliver both.
The BASHIR® Endovascular Device and BASHIR® S-B Endovascular Device are FDA cleared for the treatment of PE and venous thrombus, supporting single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) with integrated mechanical clot fragmentation and targeted thrombolytic delivery. The BASHIR® Plus Endovascular Device offers variable shaft infusion lengths to address venous thrombus with extensive clot burden in a broader range of anatomical presentations.
Thrombolex.com #thrombolex ... See MoreSee Less
0 CommentsComment on Facebook
For PERT teams, procedural efficiency is not measured in minutes alone. It is measured in the consistency, safety, and clinical confidence delivered for every patient.
In clinical experience with on-the-table (OTT) pharmaco-mechanical lysis (PML) using the BASHIR® Endovascular Device for intermediate-risk PE, the median procedure time was approximately 39 minutes, with no major bleeding events observed in the reported cohort and no requirement for post-procedure infusion. This kind of structured, reproducible outcome is what PERT programs need to build clinical confidence across their institutions.
Thrombolex.com #thrombolex ... See MoreSee Less
0 CommentsComment on Facebook
In PE care, what happens after the procedure matters as much as what happens during it.
Single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML) using the BASHIR® Endovascular Device is designed to support targeted clot fragmentation and thrombolytic delivery in a structured, efficient intervention, without the need for post-procedure infusion. Clinical experience has demonstrated no major bleeding events in the reported cohort, supporting a pathway that reduces intensive care utilization and total length of hospital stay.
For institutions managing acute PE patients, that kind of post-procedure efficiency is not incidental. It is part of what makes a clinically proven solution worth choosing.
Thrombolex.com #thrombolex ... See MoreSee Less
0 CommentsComment on Facebook
A strong PERT program depends on having reliable, consistent tools that fit the way your team works.
The BASHIR® Endovascular Device is a standalone technology that requires no capital equipment and integrates into existing lab workflows across a broad range of healthcare facilities. Designed to support single-session, on-the-table (OTT) pharmaco-mechanical lysis (PML), it gives PERT teams a targeted, clinically proven solution that delivers procedural consistency and clinical confidence, without adding complexity to an already demanding care environment.
Thrombolex.com #thrombolex ... See MoreSee Less
0 CommentsComment on Facebook
The BASHIR® Endovascular Device's expandable infusion basket is engineered for mechanical fragmentation along with uniform delivery of thrombolytics to the segmental branches of the pulmonary arteries, creating focused pharmacologic exposure precisely where clot burden is greatest. This integrated approach supports a controlled, structured intervention that maintains procedural consistency from the first step to the last.
It is not just about where the therapy goes. It is about how reliably it gets there.
Thrombolex.com #Thrombolex ... See MoreSee Less
0 CommentsComment on Facebook